Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 4 Summary of changes in all survey responses by treatment and time

From: Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial

   Placebo Ambrisentan
Measure Change period Change (95% CI) Change P -value Overall P -value Change (95% CI) Change P -value Overall P -value
S-HAQ 1 W - Base −0.13 (−0.33,0.08) 0.22 0.14 −0.12 (−0.23,-0.00) 0.048 0.005
  12 W - Base −0.20 (−0.40,0.00) 0.051   −0.20 (−0.32,-0.08) 0.001  
  12 W - 1 W −0.08 (−0.28,0.13) 0.45   −0.09 (−0.21,0.03) 0.15  
RCS 1 W - Base −0.20 (−1.74,1.34) 0.79 0.95 0.20 (−0.69,1.09) 0.65 0.001
  12 W - Base −0.20 (−1.74,1.34) 0.79   −1.46 (−2.37,-0.55) 0.002  
  12 W - 1 W −0.00 (−1.54,1.54) 0.99   −1.66 (−2.57,-0.75) <0.001  
P-VAS 1 W - Base 0.20 (−0.95,1.35) 0.73 0.19 −0.47 (−1.13,0.20) 0.16 0.14
  12 W - Base −0.80 (−1.95,0.35) 0.17   −0.66 (−1.35,0.02) 0.056  
  12 W - 1 W −1.00 (−2.15,0.15) 0.087   −0.20 (−0.88,0.49) 0.56  
  1. P-values are from repeated measure analysis of variance models. Base = baseline; W = week; CI, confidence interval; P-VAS, Visual Analog Scale for Pain; RCS, Raynaud’s Condition Score; S-HAQ, Scleroderma Health Assessment Questionnaire.